These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26147369)

  • 1. Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets.
    Cox RJ; Major D; Pedersen G; Pathirana RD; Hoschler K; Guilfoyle K; Roseby S; Bredholt G; Assmus J; Breakwell L; Campitelli L; Sjursen H
    PLoS One; 2015; 10(7):e0131652. PubMed ID: 26147369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.
    Sun X; Belser JA; Pulit-Penaloza JA; Creager HM; Guo Z; Jefferson SN; Liu F; York IA; Stevens J; Maines TR; Jernigan DB; Katz JM; Levine MZ; Tumpey TM
    Virology; 2017 Aug; 508():164-169. PubMed ID: 28554058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
    Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.
    Pedersen G; Major D; Roseby S; Wood J; Madhun AS; Cox RJ
    Influenza Other Respir Viruses; 2011 Nov; 5(6):426-37. PubMed ID: 21668670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection.
    Pedersen GK; Madhun AS; Breakwell L; Hoschler K; Sjursen H; Pathirana RD; Goudsmit J; Cox RJ
    J Infect Dis; 2012 Jul; 206(2):158-66. PubMed ID: 22551811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial.
    Cox RJ; Pedersen G; Madhun AS; Svindland S; Sævik M; Breakwell L; Hoschler K; Willemsen M; Campitelli L; Nøstbakken JK; Weverling GJ; Klap J; McCullough KC; Zambon M; Kompier R; Sjursen H
    Vaccine; 2011 Oct; 29(45):8049-59. PubMed ID: 21864624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine.
    Baras B; Stittelaar KJ; Simon JH; Thoolen RJ; Mossman SP; Pistoor FH; van Amerongen G; Wettendorff MA; Hanon E; Osterhaus AD
    PLoS One; 2008 Jan; 3(1):e1401. PubMed ID: 18167560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge.
    Major D; Chichester JA; Pathirana RD; Guilfoyle K; Shoji Y; Guzman CA; Yusibov V; Cox RJ
    Hum Vaccin Immunother; 2015; 11(5):1235-43. PubMed ID: 25714901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
    Heldens JG; Glansbeek HL; Hilgers LA; Haenen B; Stittelaar KJ; Osterhaus AD; van den Bosch JF
    Vaccine; 2010 Nov; 28(51):8125-31. PubMed ID: 20950729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
    J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man.
    Pedersen GK; Sjursen H; Nøstbakken JK; Jul-Larsen Å; Hoschler K; Cox RJ
    Hum Vaccin Immunother; 2014; 10(8):2408-16. PubMed ID: 25424948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
    Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
    Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
    Tambyah PA; Wilder-Smith A; Pavlova BG; Barrett PN; Oh HM; Hui DS; Yuen KY; Fritsch S; Aichinger G; Loew-Baselli A; van der Velden M; Maritsch F; Kistner O; Ehrlich HJ
    Vaccine; 2012 Jan; 30(2):329-35. PubMed ID: 22080174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge.
    Mann AJ; Noulin N; Catchpole A; Stittelaar KJ; de Waal L; Veldhuis Kroeze EJ; Hinchcliffe M; Smith A; Montomoli E; Piccirella S; Osterhaus AD; Knight A; Oxford JS; Lapini G; Cox R; Lambkin-Williams R
    PLoS One; 2014; 9(5):e93761. PubMed ID: 24850536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.
    Schwarz TF; Horacek T; Knuf M; Damman HG; Roman F; Dramé M; Gillard P; Jilg W
    Vaccine; 2009 Oct; 27(45):6284-90. PubMed ID: 19856521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.
    van der Velden MV; Aichinger G; Pöllabauer EM; Löw-Baselli A; Fritsch S; Benamara K; Kistner O; Müller M; Zeitlinger M; Kollaritsch H; Vesikari T; Ehrlich HJ; Barrett PN
    Vaccine; 2012 Sep; 30(43):6127-35. PubMed ID: 22884662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination.
    Pedersen GK; Höschler K; Øie Solbak SM; Bredholt G; Pathirana RD; Afsar A; Breakwell L; Nøstbakken JK; Raae AJ; Brokstad KA; Sjursen H; Zambon M; Cox RJ
    Vaccine; 2014 Jul; 32(35):4550-4557. PubMed ID: 24950357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
    Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
    Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.